阿片类药物使用障碍 (OUD) 市场报告：趋势、预测和竞争分析（至 2030 年）

阿片类药物使用障碍 (OUD) 趋势和预测

全球阿片类药物使用障碍（OUD）市场的未来看起来充满希望，医院药房和零售药房市场充满机会。到 2030 年，全球阿片类药物使用障碍 (OUD) 市场预计将达到 72 亿美元，2024 年至 2030 年复合年增长率为 10.3%。这个市场的主要驱动因素是癌症、心血管疾病、整形外科疾病等慢性疾病的盛行率不断上升，人们越来越认识到Buprenornhine贴片是一种有效的治疗选择。

• 按药物类型划分，Lucintel 预测，由于人口老化和阿片类药物滥用盛行率的增加，促效剂在预测期内仍将占据很大一部分。
• 从分销管道来看，由于政府在医疗保健基础设施上的支出增加，医院药房将继续成为一个重要的细分市场。
• 从地区来看，由于阿片类药物滥用治疗药物的上市和核准数量不断增加，预计北美在预测期内仍将是最大的地区。

阿片类药物使用障碍 (OUD) 市场的策略性成长机会

阿片类药物使用障碍 (OUD) 市场在各种应用中提供了多种策略性成长机会。透过利用这些机会，我们可以改善治疗结果、扩大可近性并有效解决持续的鸦片危机。

• 扩大 MAT 计划：将戒毒治疗援助计划扩展到服务不足的地区可提供巨大的成长潜力。增加Buprenornhine和美沙酮等 MAT 选项可以改善 OUD 患者获得有效治疗的机会。
• 数位健康解决方案的整合：数位健康解决方案（包括远端医疗和行动应用程式）的整合提供了成长机会。这些工具将增强治疗服务、患者参与和监测，并为市场扩张开闢新途径。
• 开发新治疗方法：投资新治疗方法的研究和开发，包括新药物配方和联合治疗，提供了成长机会。解决未满足需求的创新治疗方法可以赢得市场占有率并改善治疗选择。
• 扩大减少危害计画：扩大有害物质减少计画有成长机会，例如针头交换服务和监督消费场所。这些计划可以减少阿片类药物使用的影响，并提供治疗和康復的途径。
• 加强综合护理模式：将 OUD 治疗与心理健康和社会支持服务相结合的综合护理模式的发展和实施提供了成长潜力。这些模型改善了患者的治疗效果并满足了 OUD 患者的多方面需求。

OUD 市场的策略性成长机会包括扩大 MAT 计画、整合数位健康解决方案、开发新颖的治疗方法、扩大危害减少倡议以及加强综合护理模式。这些机会符合市场不断变化的需求，可以推动治疗和復原结果的显着改善。

阿片类药物使用障碍 (OUD) 市场驱动因素与挑战

阿片类药物使用障碍 (OUD) 市场受到各种驱动因素​​和挑战的显着影响，包括技术进步、经济因素和监管变化。促进因素包括治疗方案的创新、认识的提高、政策改革、经济奖励和改善治疗的可近性。同时，挑战包括监管障碍、经济障碍以及治疗依从性和可及性问题。了解这些因素对于寻求应对 OUD 市场复杂性并加强有效治疗和管理策略的相关人员至关重要。

推动阿片类药物使用障碍（OUD）市场的因素是：

1.技术进步：数位健康工具和先进药物处方等治疗技术的创新正在推动OUD市场的成长。数位平台促进远端监控、远端医疗和个人化治疗计划，以提高患者参与度和治疗结果。新的药物配方，包括缓释性方案，正在提高治疗的有效性和便利性，并有助于不断增长的市场需求。

2. 提高认识和教育：阿片类药物危机和对 OUD 认识的提高导致对有效治疗的需求增加。教育宣传活动和公共卫生工作正在增进对鸦片类药物成瘾的了解，减少耻辱并鼓励治疗。随着越来越多的人意识到对 OUD 管理解决方案的需求，这种不断增长的意识正在推动市场成长。

3. 政策和监管改革：透过政策和政策变化，获得 OUD 待遇的机会有所改善。 《药物辅助性治疗(MAT) 保险覆盖范围扩大和支持法案》等政府措施正在减少治疗障碍。这些改革鼓励医疗保健提供者提供更广泛的治疗选择，并改善患者的整体治疗机会。

4. 财政奖励和资金：政府和私人资金的增加正在支持 OUD 治疗计划和研究。经济奖励，例如对 MAT 的津贴和对成瘾治疗设施的津贴，使医疗保健提供者更容易提供全面治疗。这种财政支持增加了治疗方法的可用性和创新，并推动了市场成长。

5. 扩大获得治疗的机会：扩大 OUD 治疗机会的努力，特别是在服务不足和农村地区，正在推动市场成长。增加治疗中心数量、提供行动治疗单位以及将治疗纳入初级卫生服务的努力正在改善可近性。这些努力正在帮助更多的人获得管理 OUD 所需的护理。

阿片类药物使用疾患 (OUD) 市场面临的挑战包括：

1. 监管障碍：满足复杂的监管要求并获得新治疗方法的核准可能很困难。地区法规的差异可能会延迟创新治疗方法的市场进入，并为广泛采用造成障碍。遵守严格的指导方针还会增加製造商的成本并限制治疗方法的可用性。

2. 财务障碍：与 OUD 治疗相关的高额费用（包括药物和治疗计划）可能是一个重大障碍。财务限制可能会限制患者获得所需治疗并影响治疗顺从性。保险覆盖范围不足和自付费用可能会进一步加剧这些挑战并影响整体市场成长。

3. 治疗依从性和可近性问题：确保一致的治疗顺从性和解决可近性问题是主要挑战。由于副作用、耻辱和缺乏支持，患者可能难以坚持治疗。治疗中心的可用性有限，尤其是在偏远地区，也会阻碍治疗中心的使用并影响 OUD 管理工作的有效性。

阿片类药物使用障碍市场是由市场驱动因素和挑战的复杂相互作用形成的。技术进步、认识提升、政策改革、经济奖励和扩大可及性是提高治疗有效性和可近性的关键驱动力。然而，监管障碍、经济障碍以及治疗依从性和可近性问题构成了重大挑战。解决这些因素对于优化市场策略和改善阿片类药物使用障碍患者的治疗结果至关重要。了解和驾驭这些动态对于寻求推进 OUD 治疗前景的相关人员至关重要。

目录

第一章执行摘要

第二章全球阿片类药物使用障碍 (OUD) 市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 市场趋势及预测分析（2018-2030）

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球阿片类药物使用障碍 (OUD) 市场趋势 (2018-2023) 和预测 (2024-2030)
• 全球阿片类药物使用障碍 (OUD) 市场：按药物类型
  • 促效剂
  • 拮抗剂
• 全球阿片类药物使用障碍 (OUD) 市场：按年龄组别
  • 19-39岁
  • 40-59岁
  • 60岁以上
• 全球阿片类药物使用障碍 (OUD) 市场：依给药途径
  • 口服
  • 静脉
  • 舌下
• 全球阿片类药物使用障碍 (OUD) 市场：按分销管道
  • 医院药房
  • 零售药房

第四章 各地区市场趋势及预测分析（2018-2030）

• 全球阿片类药物使用障碍 (OUD) 市场：按地区
• 北美阿片类药物使用疾患 (OUD) 市场
• 欧洲阿片类药物使用障碍 (OUD) 市场
• 亚太地区阿片类药物使用障碍 (OUD) 市场
• 其他地区阿片类药物使用障碍（OUD）市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球阿片类药物使用障碍 (OUD) 市场成长机会：按药物类型
  • 全球阿片类药物使用障碍 (OUD) 市场成长机会：按年龄组别
  • 全球阿片类药物使用障碍 (OUD) 市场成长机会：按给药途径
  • 全球阿片类药物使用障碍 (OUD) 市场成长机会：按分销管道
  • 全球阿片类药物使用障碍 (OUD) 市场成长机会：按地区
• 全球阿片类药物使用障碍 (OUD) 市场的新兴趋势
• 战略分析
  • 新产品开发
  • 全球阿片类药物使用障碍（OUD）市场容量扩张
  • 全球阿片类药物使用障碍 (OUD) 市场的企业合併(M&A) 和合资企业
  • 认证和许可

第七章主要企业简介

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) Trends and Forecast

The future of the global opioid use disorder (OUD) market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global opioid use disorder (OUD) market is expected to reach an estimated $7.2 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are the growing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and orthopedic diseases, and the increasing recognition of buprenorphine patches as an efficient treatment option.

• Lucintel forecasts that, within the drug type category, agonists will remain the larger segment over the forecast period due to the growing aging population and increase in the prevalence of opioid abuse.
• Within the distribution channel category, hospital pharmacies will remain the larger segment due to rising expenditure by the government to develop healthcare infrastructure.
• In terms of regions, North America will remain the largest region over the forecast period due to a rise in the number of product launches and product approval for opioid use disorder.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Opioid Use Disorder (OUD) Market

Emerging trends in the opioid use disorder (OUD) market are shaping the future of treatment with advancements in medication, technology, and holistic approaches. These trends reflect a shift towards more comprehensive and personalized care strategies.

• Increased Use of Digital Health Technologies: Digital health technologies

s, including telemedicine and mobile health apps, are being increasingly integrated into OUD treatment plans. These tools provide remote monitoring, virtual counseling, and personalized treatment adjustments, improving patient engagement and access to care.

• Advancements in Medication-Assisted Treatment (MAT): There have been significant innovations in MAT, including extended-release formulations and novel combination therapies. These advancements enhance treatment adherence and reduce the potential for misuse, offering more effective and long-lasting solutions for managing OUD.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are gaining traction. This holistic approach addresses the multifaceted needs of patients, improving overall outcomes and reducing the risk of relapse.
• Expansion of Harm Reduction Programs: Harm reduction strategies, such as needle exchange programs and supervised consumption sites, are being expanded. These programs aim to reduce the negative health consequences of drug use and provide pathways to treatment and recovery.
• Emphasis on Personalized Medicine: Personalized medicine approaches, including genetic testing and individualized treatment plans, are becoming more prevalent. These strategies tailor treatment to the specific needs and characteristics of each patient, improving efficacy and minimizing side effects.

These emerging trends are reshaping the OUD market by introducing more effective, personalized, and integrated approaches to treatment. The focus on digital health, advanced medications, and holistic care models reflects a shift towards improving patient outcomes and addressing the complex needs of those affected by opioid use disorder.

Recent Developments in the Opioid Use Disorder (OUD) Market

Recent developments in the opioid use disorder (OUD) market have focused on improving treatment options, expanding access, and enhancing support systems. These changes are driven by the ongoing need to address the opioid crisis and provide effective, comprehensive care.

• Expansion of Medication-Assisted Treatment (MAT): New MAT formulations and extended-release options have been introduced, improving treatment adherence and efficacy. Innovations in buprenorphine and naltrexone formulations offer better management of withdrawal symptoms and relapse prevention.
• Integration of Digital Tools: The adoption of digital health tools, including telemedicine platforms and mobile apps, has enhanced the delivery of OUD treatment. These tools facilitate remote monitoring, virtual counseling, and data-driven adjustments to treatment plans.
• Strengthening Harm Reduction Initiatives: Governments and organizations have increased funding and support for harm reduction programs. Needle exchange programs, supervised consumption sites, and naloxone distribution efforts are expanding, aiming to reduce the negative impact of opioid use.
• Policy and Regulatory Changes: New regulations and policies have been implemented to improve access to OUD treatments and support services. Policies include expanded insurance coverage for MAT and initiatives to reduce stigma and increase public awareness.
• Focus on Integrated Care Models: Integrated care models that combine OUD treatment with mental health and social support services are being promoted. These models address the comprehensive needs of patients and enhance overall treatment effectiveness.

These recent developments reflect a concerted effort to improve OUD treatment and support systems. By focusing on medication advancements, digital tools, harm reduction, policy changes, and integrated care, the market is evolving to better address the complexities of opioid use disorder and support patient recovery.

Strategic Growth Opportunities for Opioid Use Disorder (OUD) Market

The opioid use disorder (OUD) market presents several strategic growth opportunities across various applications. Leveraging these opportunities can enhance treatment outcomes, expand access, and address the ongoing opioid crisis effectively.

• Expansion of MAT Programs: Expanding medication-assisted treatment programs to underserved areas offers significant growth potential. Increasing the availability of MAT options, such as buprenorphine and methadone, can improve access to effective treatment for those struggling with OUD.
• Integration of Digital Health Solutions: The incorporation of digital health solutions, including telemedicine and mobile apps, provides growth opportunities. These tools enhance treatment delivery, patient engagement, and monitoring, creating new avenues for market expansion.
• Development of Novel Therapies: Investing in research and development of novel therapies, such as new drug formulations and combination treatments, presents growth opportunities. Innovative therapies that address unmet needs can capture market share and offer improved treatment options.
• Expansion of Harm Reduction Programs: Expanding harm reduction programs, such as needle exchange services and supervised consumption sites, offers growth opportunities. These programs can reduce the impact of opioid use and provide pathways to treatment and recovery.
• Enhancement of Integrated Care Models: Developing and implementing integrated care models that combine OUD treatment with mental health and social support services presents growth potential. These models improve patient outcomes and address the multifaceted needs of individuals with OUD.

Strategic growth opportunities in the OUD market include expanding MAT programs, integrating digital health solutions, developing novel therapies, scaling harm reduction initiatives, and enhancing integrated care models. These opportunities align with the evolving needs of the market and can drive significant improvements in treatment and recovery outcomes.

Opioid Use Disorder (OUD) Market Driver and Challenges

The opioid use disorder (OUD) market is significantly influenced by various drivers and challenges that encompass technological advancements, economic factors, and regulatory changes. The drivers include innovations in treatment options, increased awareness, policy reforms, economic incentives, and improved access to care. Challenges, on the other hand, involve regulatory hurdles, economic barriers, and issues related to treatment adherence and accessibility. Understanding these factors is crucial for stakeholders aiming to navigate the complexities of the OUD market and enhance strategies for effective treatment and management.

The factors responsible for driving the opioid use disorder (OUD) market include:

1. Technological Advancements: Innovations in treatment technologies, such as digital health tools and advanced medication formulations, are driving growth in the OUD market. Digital platforms facilitate remote monitoring, telemedicine, and personalized treatment plans, improving patient engagement and outcomes. New drug formulations, including extended-release options, enhance the efficacy and convenience of treatment, contributing to increased market demand.

2. Increased Awareness and Education: Growing awareness about the opioid crisis and OUD has led to increased demand for effective treatments. Educational campaigns and public health initiatives are improving understanding of opioid addiction, reducing stigma, and encouraging individuals to seek treatment. This heightened awareness is driving market growth as more people recognize the need for OUD management solutions.

3. Policy and Regulatory Reforms: Changes in policies and regulations are facilitating better access to OUD treatments. Government initiatives, such as expanded insurance coverage for medication-assisted treatment (MAT) and supportive legislation, are reducing barriers to care. These reforms are encouraging healthcare providers to offer a wider range of treatment options and improving overall access for patients.

4. Economic Incentives and Funding: Increased funding from government and private sources is supporting OUD treatment programs and research. Economic incentives, such as subsidies for MAT and grants for addiction treatment facilities, are making it easier for providers to offer comprehensive care. This financial support is driving market growth by enhancing treatment availability and innovation.

5. Expansion of Treatment Access: Efforts to expand access to OUD treatments, particularly in underserved and rural areas, are driving market growth. Initiatives to increase the number of treatment centers, provide mobile treatment units, and integrate care into primary health services are improving accessibility. These efforts are ensuring that more individuals can receive the necessary care for managing OUD.

Challenges in the opioid use disorder (OUD) market include:

1. Regulatory Hurdles: Navigating complex regulatory requirements and obtaining approvals for new treatments can be challenging. Variability in regulations across regions can delay market entry for innovative therapies and create barriers to widespread adoption. Compliance with stringent guidelines can also increase costs for manufacturers and limit treatment availability.

2. Economic Barriers: High costs associated with OUD treatments, including medications and therapy programs, can be a significant barrier. Economic constraints may limit patient access to necessary care and affect treatment adherence. Insufficient insurance coverage and out-of-pocket expenses can further exacerbate these challenges, impacting overall market growth.

3. Treatment Adherence and Accessibility Issues: Ensuring consistent treatment adherence and addressing accessibility issues pose significant challenges. Patients may struggle with adherence due to side effects, stigma, or lack of support. Limited availability of treatment centers, particularly in remote areas, can also hinder access and affect the effectiveness of OUD management efforts.

The opioid use disorder market is shaped by a complex interplay of drivers and challenges. Technological advancements, increased awareness, policy reforms, economic incentives, and expanded access are key drivers that enhance treatment effectiveness and availability. However, regulatory hurdles, economic barriers, and issues with treatment adherence and accessibility present significant challenges. Addressing these factors is crucial for optimizing market strategies and improving outcomes for individuals affected by opioid use disorder. Understanding and navigating these dynamics will be essential for stakeholders seeking to advance the OUD treatment landscape.

List of Opioid Use Disorder (OUD) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies opioid use disorder (OUD) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the opioid use disorder (OUD) companies profiled in this report include-

• Hikma Pharmaceuticals
• Indivior
• Titan Pharmaceuticals
• Reckitt Benckiser Pharmaceuticals
• Camurus
• BioDelivery Sciences International
• Sandoz

Opioid Use Disorder (OUD) by Segment

The study includes a forecast for the global opioid use disorder (OUD) by drug type, age group, route of administration, distribution channel, and region.

Opioid Use Disorder (OUD) Market by Drug Type [Analysis by Value from 2018 to 2030]:

• Agonist
• Antagonist

Opioid Use Disorder (OUD) Market by Age Group [Analysis by Value from 2018 to 2030]:

• 19 To 39
• 40 To 59
• Age 60 and Over

List of Opioid Use Disorder (OUD) Companies

Opioid Use Disorder (OUD) Market by Route of Administration [Analysis by Value from 2018 to 2030]:

• Oral
• Intravenous
• Sublingual

Opioid Use Disorder (OUD) Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific

Opioid Use Disorder (OUD) Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy

Country Wise Outlook for the Opioid Use Disorder (OUD) Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below is a summary of recent developments by major opioid use disorder producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the US, there has been a notable increase in the availability of naloxone and buprenorphine, with expanded access through recent legislation. The FDA approved new formulations of buprenorphine for enhanced efficacy and ease of use. Additionally, federal and state governments are implementing comprehensive strategies, including expanded treatment facilities and harm reduction programs.
• China: China has been focusing on improving access to opioid dependence treatments, including methadone maintenance therapy (MMT) and buprenorphine. Recent policy changes have aimed to integrate OUD treatment into broader healthcare services. Efforts to increase public awareness and reduce stigma around addiction are also being emphasized.
• Germany: Germany has advanced its treatment protocols with new guidelines incorporating both pharmacological and psychosocial interventions. The integration of digital health solutions, such as telemedicine for therapy management, has been a key development. Increased funding for addiction treatment services has also been noted.
• India: In India, there is a growing focus on increasing access to OUD treatments, with an emphasis on expanding methadone and buprenorphine programs. Recent developments include the establishment of more treatment centers and community-based programs. Public awareness campaigns are being strengthened to combat stigma and promote treatment options.
• Japan: Japan has introduced new regulations to improve access to opioid treatment programs. There has been an increase in the availability of treatment options such as buprenorphine and extended-release naltrexone. Additionally, efforts to enhance coordination between healthcare providers and support systems have been a focus.

Features of the Global Opioid Use Disorder (OUD) Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the opioid use disorder (OUD) market by drug type (agonist and antagonist), age group (19 to 39, 40 to 59, and age 60 and over), route of administration (oral, intravenous, and sublingual), distribution channel (hospital pharmacy and retail pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Opioid Use Disorder (OUD) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Opioid Use Disorder (OUD) Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Opioid Use Disorder (OUD) Market by Drug Type
  • 3.3.1: Agonist
  • 3.3.2: Antagonist
• 3.4: Global Opioid Use Disorder (OUD) Market by Age Group
  • 3.4.1: 19 to 39
  • 3.4.2: 40 to 59
  • 3.4.3: Age 60 and over
• 3.5: Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 3.5.1: Oral
  • 3.5.2: Intravenous
  • 3.5.3: Sublingual
• 3.6: Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 3.6.1: Hospital pharmacy
  • 3.6.2: Retail Pharmacy

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Opioid Use Disorder (OUD) Market by Region
• 4.2: North American Opioid Use Disorder (OUD) Market
  • 4.2.1: North American Market by Drug Type: Agonist and Antagonist
  • 4.2.2: North American Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.3: European Opioid Use Disorder (OUD) Market
  • 4.3.1: European Market by Drug Type: Agonist and Antagonist
  • 4.3.2: European Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.4: APAC Opioid Use Disorder (OUD) Market
  • 4.4.1: APAC Market by Drug Type: Agonist and Antagonist
  • 4.4.2: APAC Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy
• 4.5: ROW Opioid Use Disorder (OUD) Market
  • 4.5.1: ROW Market by Drug Type: Agonist and Antagonist
  • 4.5.2: ROW Market by Distribution Channel: Hospital pharmacy and Retail Pharmacy

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Age Group
  • 6.1.3: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Route of Administration
  • 6.1.4: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Distribution Channel
  • 6.1.5: Growth Opportunities for the Global Opioid Use Disorder (OUD) Market by Region
• 6.2: Emerging Trends in the Global Opioid Use Disorder (OUD) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Opioid Use Disorder (OUD) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Opioid Use Disorder (OUD) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Hikma Pharmaceuticals
• 7.2: Indivior
• 7.3: Titan Pharmaceuticals
• 7.4: Reckitt Benckiser Pharmaceuticals
• 7.5: Camurus
• 7.6: BioDelivery Sciences International
• 7.7: Sandoz